News and Trends 3 Mar 2023
Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor
Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted…